AI in Medical Research: A Glossary Reference on Technologies, Applications, and Limitations

Definition and Scope of AI in Medical Research

Artificial intelligence in medical research refers to the application of computational systems that perform tasks typically requiring human intelligence — pattern recognition, prediction, natural language understanding, and decision-making — across the entire lifecycle of biomedical investigation. This spans from the earliest stages of target identification and molecule design through preclinical testing, clinical trial execution, medical image analysis, and the synthesis and publication of scientific findings.

The field is not monolithic. It encompasses several distinct technology families — machine learning (ML), deep learning (DL), natural language processing (NLP), large language models (LLMs), generative AI, and emerging AI agents — each with different strengths, data requirements, and limitations. Understanding which technology is appropriate for which research task is essential for both practitioners and evaluators.

This glossary entry provides a structured reference for healthcare professionals and clinical researchers seeking a rigorous, evidence-grounded overview of how AI is deployed across the medical research lifecycle. It maps core technologies to major application areas, presents concrete data points from recent implementations, and systematically addresses the limitations and risks that accompany each approach.

Core AI Technologies in Medical Research

Each AI technology family plays a distinct role in the research pipeline. The table below summarizes the primary technologies, their typical functions, and where they are most commonly applied.

These technologies are not mutually exclusive. A single research project may combine DL for image analysis, NLP for extracting clinical variables from notes, and ML for building a predictive model. The trend in 2026 is toward integration: agentic systems that orchestrate multiple AI tools to execute complex workflows with minimal human intervention.

Key Application Areas with Evidence

Drug Discovery and Development

AI has become a central tool in pharmaceutical R&D, particularly for target identification, generative molecule design, and predictive safety assessment. Novartis provides a well-documented example of the full pipeline in action. Using AI-driven simulations and literature mining, the company identified five promising targets for autosomal dominant polycystic kidney disease (ADPKD) in under a year — a process that traditionally takes several years. For a molecular glue degrader program, AI computationally designed 15 million potential compounds; only approximately 60 molecules were synthesized in the lab to arrive at a potent, brain-penetrant candidate. On the safety side, Novartis's Data42 platform — a data lake containing over 30 years of clinical and preclinical data — generates activity profiles that predict cardiac toxicity from candidate compounds.

Beyond individual company efforts, the broader landscape shows accelerating momentum. As of mid-2026, eight leading AI-native biotech companies — including Insilico Medicine, BenevolentAI, and Atomwise (now Numerion Labs) — have advanced a combined 31 drugs into human clinical trials. Protein structure prediction tools such as AlphaFold 3 and RoseTTAFold All-Atom have compressed timelines for target validation from years to weeks, enabling researchers to model protein-ligand interactions with atomic-level accuracy.

Clinical Trial Optimization

AI is increasingly used to address the high cost and low efficiency of clinical trials. Key applications include automated patient cohort identification from electronic health records, emulation of randomized controlled trials using real-world data, and predictive modeling of trial outcomes.

The Mayo Clinic Platform (MCP), described in a February 2026 paper in npj Health Systems, exemplifies the infrastructure required for these tasks. MCP is a secure cloud-based environment providing de-identified data on over 15.1 million patients, 12 billion radiology images, 3.2 billion lab results, and 1.65 billion clinical notes. Researchers have used MCP to conduct RCT emulations for heart failure drugs, validate the hypothesis that antihypertensives reduce dementia risk, develop a BiGRU deep learning model predicting progression from mild cognitive impairment to Alzheimer's disease, and build a model predicting major adverse cardiovascular events after liver transplantation. The platform supports both no-code tools (Cohort Visualizer) and code-enabled workspaces (JupyterLab, RStudio) with computing configurations up to 208 CPU cores, 1872 GB RAM, and 8 NVIDIA H100 80GB GPUs.

Medical Imaging and Diagnosis

Medical imaging remains the most mature application area for AI in clinical research. Deep learning models have demonstrated high accuracy in cancer detection (mammography, lung CT, dermatoscopy), cardiac monitoring (echocardiogram interpretation, ECG analysis), and neurodegenerative disease phenotyping.

Tools such as PathChat (a pathology-specific vision-language AI) and DeepDR (a deep learning system for diabetic retinopathy screening) have shown clinical utility in research settings. The UW-Madison School of Medicine and Public Health reported in March 2026 that an AI model analyzing pathology slides identified sex-specific risk factors for glioblastoma using data from over 250 studies — a finding that would be impractical to derive through manual literature review alone.

Precision Medicine and Genomics

AI enables the analysis of high-dimensional genomic, proteomic, and clinical data to identify biomarkers, stratify patient populations, and uncover disease mechanisms. The COSIME machine learning algorithm, developed at UW-Madison, is designed to analyze two large datasets simultaneously to decipher mechanisms in neurodevelopmental and neurodegenerative diseases. Other AI models are being developed for deep phenotyping of Alzheimer's co-pathologies — distinguishing, for example, between Alzheimer's disease, Lewy body dementia, and mixed pathologies from imaging and biomarker data.

Machine learning on EHR data is also being used to develop decision-support systems for earlier diagnosis of conditions that are typically detected late, such as ovarian cancer. These models integrate structured data (lab results, vital signs) with unstructured clinical notes to identify subtle patterns that precede formal diagnosis.

Scientific Writing and Publishing

LLMs such as ChatGPT are increasingly used by researchers for drafting manuscripts, generating abstracts, editing, plagiarism detection, and citation formatting. A PRISMA-guided literature review published in February 2025 catalogued these applications and noted that AI tools can assist with journal matching and peer review quality control.

However, the same review identified significant risks: potential biases in AI-generated content, copyright and ownership ambiguities, and the concern that LLMs may function as "stochastic parrots" that produce plausible-sounding but factually unreliable text. A 2023 review in PMC that was itself written with ChatGPT assistance found that only 6% of the AI-generated references were correct — a stark illustration of the hallucination problem that makes unverified LLM output unsuitable for scientific publication.

Concrete Evidence and Data Points

The following table consolidates the most impactful quantitative and qualitative evidence from recent implementations, organized by application area. Each entry is sourced from peer-reviewed literature, institutional announcements, or regulatory documents.

Limitations and Risks

The evidence for AI in medical research is accompanied by well-documented limitations that researchers and evaluators must consider. These fall into several categories.

Data Quality and Availability

AI models are fundamentally dependent on the quality, completeness, and representativeness of their training data. Biomedical datasets are often siloed across institutions, encoded in incompatible formats, and biased toward specific populations (e.g., predominantly white, urban, or high-income cohorts). The 2023 PMC drug discovery review identified the availability of suitable high-quality data as a key challenge, noting that models trained on narrow or homogeneous datasets may fail to generalize to broader patient populations.

Algorithmic Bias

Bias can enter AI systems at multiple points: through unrepresentative training data, through the choice of outcome variables, or through the way model predictions are used in decision-making. In medical research, biased models can lead to incorrect conclusions about treatment effects, misdiagnosis in underrepresented groups, or the development of drugs that are less effective for certain populations. The PRISMA-guided review on AI in medical research flagged algorithmic bias as a central ethical concern requiring ongoing monitoring and mitigation.

LLM Hallucination and Reliability

Large language models are prone to "hallucination" — generating text that is fluent, plausible, and factually incorrect. The 2023 PMC review that found only 6% of ChatGPT's references were correct is a concrete example of this risk. In scientific writing, hallucinated citations, fabricated data, or misinterpreted findings can propagate errors into the literature if not caught by human reviewers. The Harvard Medical School article on AI in clinical research noted that AI "can hallucinate or over-generalize" and that it forces users to engage in higher-level thinking to assess its suggestions.

Reproducibility Failures

A growing body of meta-research has documented that many AI studies in healthcare suffer from methodological weaknesses: small sample sizes, lack of external validation, incomplete reporting of model architecture and hyperparameters, and failure to preregister analyses. These issues undermine the reproducibility of findings and make it difficult to assess whether a reported performance metric (e.g., AUC 0.95) would hold in a different clinical setting. The CONSORT-AI reporting standard was developed specifically to address these gaps in clinical trials of AI interventions.

Dual-Use and Safety Risks

AI tools designed for beneficial purposes can be repurposed for harm. A 2022 paper in Nature Machine Intelligence demonstrated that researchers could invert the drug discovery process to design over 40,000 toxic molecules in just six hours. The Stanford HAI consortium that reported this finding identified three pressing risk areas: AI in drug discovery for creating toxic agents or bioweapons, AI-generated synthetic data leading to fake or misleading results, and ambient intelligence for potential surveillance or privacy violations. The consortium recommended embedding protective measures in AI models, continuous auditing, and protocols to stop endeavors where risks outweigh benefits.

2026 Outlook: Agentic AI and Foundation Models

The trajectory of AI in medical research in 2026 is defined by two major trends: the emergence of agentic AI systems and the maturation of foundation models.

Mass General Brigham researchers, writing in December 2025, predicted that 2026 would see medical AI move from the "Peak of Inflated Expectations" to the early "Slope of Enlightenment" as real-world evidence exposes issues like bias and workflow fit. They specifically forecast a shift from narrow single-purpose AI tools toward agentic systems that orchestrate complex clinical workflows, integrating multimodal data and coordinating care with clinicians in the loop. Early versions of these systems are expected to appear in radiology and pathology.

Foundation models — large, pre-trained AI models that can be fine-tuned for multiple downstream tasks — are also reshaping the research landscape. These models can be applied to tasks as diverse as molecule property prediction, protein structure modeling, and clinical text analysis without requiring task-specific training from scratch. The Mayo Clinic Platform's support for large-scale AI workloads (including NVIDIA H100 GPUs) reflects the infrastructure demands of these models.

A study from MedUni Vienna and CeMM, published in January 2026, investigated the potential of AI agents in biomedical research and found that current systems lead to significant efficiency gains, with order-of-magnitude speedups for automated data analysis and knowledge synthesis. Using a model of a multi-year molecular biology project, the authors estimated that acceleration of all "compressible" tasks could speed up progress tenfold. However, an exploratory survey of eight leading biomedical researchers indicated skepticism about drastic acceleration of hypothesis formation — the most creative and least automatable part of the research process.

References and Further Reading

The following sources were cited in this glossary entry and provide additional detail for readers who wish to explore specific topics further.

• Advancing Medical Research Through Artificial Intelligence: Progressive and Transformative Strategies — A PRISMA-guided literature review of 42 studies on AI in medical research, published February 2025 in PMC.
• The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies — A 2023 PMC review that documents the 6% correct references finding and discusses data quality and bias challenges.
• Here's How AI Is Reshaping Drug Discovery — A January 2026 World Economic Forum article by Novartis President Fiona Marshall detailing the 15-million-compound design and ADPKD target identification.
• Accelerating AI Innovation in Healthcare: Real-World Clinical Research Applications on the Mayo Clinic Platform — A February 2026 paper in npj Health Systems describing the 15.1M-patient platform and its research applications.
• How AI Is Advancing Medical Research — A March 2026 UW-Madison article covering the opioid screening study, glioblastoma risk factor analysis, and other projects.
• Looking Ahead: Predictions for Artificial Intelligence and Medicine in 2026 — A December 2025 Mass General Brigham article forecasting agentic AI and the shift from inflated expectations to real-world evidence.
• Managing Risks in AI-Powered Biomedical Research — A Stanford HAI article reporting the 40,000 toxic molecules finding and the consortium's ethical framework.
• Potential and Limitations of AI in Biomedical Research — A January 2026 MedUni Vienna study on AI agents and the tenfold acceleration estimate.
• Artificial Intelligence for Drug Development — FDA CDER page documenting over 500 AI-inclusive drug submissions from 2016-2023 and the January 2025 draft guidance.
• AI in Clinical Research: Opportunities, Limitations, and What Comes Next — A June 2025 Harvard Medical School article on the need for human oversight and the limitations of AI in hypothesis generation.